<DOC>
	<DOCNO>NCT02347657</DOCNO>
	<brief_summary>This Phase 3 , randomize , double blind , placebo control , parallel group , multicenter study people CF homozygous F508del CFTR mutation .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled , Parallel-Group Study Evaluate Efficacy Safety VX-661 Combination With Ivacaftor</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , parallel-group , multicenter study people CF homozygous F508del-CFTR mutation . This study design evaluate efficacy safety VX-661 combination ivacaftor . The active treatment regimen comprise morning dose fixed-dose combination tablet 100 mg VX-661/150 mg ivacaftor daily ( qd ) even dose ivacaftor 150 mg take approximately 12 hour morning dose . The placebo regimen visually match tablet take schedule active treatment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508del CFTR mutation , genotype confirm Screening Visit Confirmed diagnosis CF define sweat chloride value ≥60 mmol/L quantitative pilocarpine iontophoresis FEV1 ≥40 % ≤90 % predict normal age , sex , height screen Stable CF disease judge investigator Willing remain stable CF medication regimen Week 24 , applicable , Safety Follow Visit History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 28 day Day 1 ( first dose study drug ) Pregnant nursing female ( female childbearing potential must negative pregnancy test Screening Day 1 ) Sexually active subject reproductive potential willing follow contraception requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Homozygous F508del CFTR Mutation</keyword>
</DOC>